ASCO 2023

Discussions and controversies on social-media: what is…

CDK4/6i in EBC: Have abema and ribo arrived in the…

ADC revolution: How can the new results be integrated…

Expanding CDK4/6i therapy in EBC: How to select…

CDK4/6 inhibitors in EBC: Amazing data, but longer…

PART1: How to de-escalate chemotherapy? What is the…

New data on Ribocilib in adjuvant setting EBC: What…

Chemotherapy de-escalation in HER2+ patients:…

From PENELOPE-B to SURVIVE

Response adapted, chemotherapy-free option in HER2+ EBC

1/3 of patients with HER2+ in future without…

Practice changing or not quite yet?

TILs are prognostic but not predictive in HER2+ EBC

My EBC highlights from ASCO23

Another proof of efficacy of immunotherapy in advanced…

Ribociclib improves iDFS

Early follow-up shows clear benefit

Ovarian function - Ovarian suppression not necessary in…

De-escalation of CT for early BC

More CDK4/6 options for EBC patients

Young patients benefit from ovarian suppression

Palbociclib after Palbociclib might not be the best…

PHERGain opens the possibility to avoid chemotherapy in…

Can we preserve our patients form chemotherapy?

Tumor-informed ctDNA likely prognostic for relapse in…

10 years update on ShortHER

White blood cells with increasing prognostic relevance?…

A challenge for clinical management

Ribociclib has arrived in the adjuvant setting

Checkpoint inhibition in endometrial cancer: new…

SOC of ovarian ablation confirmed in meta-analysis.

First data with adjuvant ribociclib

Discussions on CDK4/6 inhibitors in EBC

Chemo-immunotherapeutic signals especially in HER2low…

TILs in HER2+ disease - prognostic, but not enough to…

TILs subtypes are associated with clinical features and…

Eine Herausforderung für viele Patienten, wenig…

TILs Subtypen sind assoziiert mit klinischen Merkmalen…

Tumor-informed ctDNA wahrscheinlich prognostisch für…

Response adaptierte, Chemotherapie-freie Option beim…

SOC der ovarialen Ablation in der Metaanalyse bestätigt

1/3 der Patientinnen mit HER2+ zukünftig ohne…

Primele date cu ribociclib adjuvant

Ovar Funktion - Ovarielle Supression verzichtbar bei…

Von PENELOPE-B zur SURVIVE

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen…

Czy wystarczy, aby zmienić standardy?

Eine Herausforderung für das klinische Management

TILs sind prognostisch aber nicht prädiktiv beim HER2+…

I miei punti salienti di ASCO23

PHERGain abre la posibilidad de evitar la quimioterapia…

NATALEE nicht überraschend aber überzeugend positiv

Palbociclib después de Palbociclib podría no ser la…

Kolejny dowód na skuteczność immunoterapii w…

E-Health Applications in Oral Cancer Therapy

Molecular imaging for endocrine responsivness

Updates on ADCs in metastatic breast cancer

What is the optimal therapie sequence for HR+ MBC…

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

The start of precision medicine in HR+ breast cancer

Aggiornamenti sugli ADC nel carcinoma mammario…

Mises à jour sur les ADC dans le cancer du sein…

CDK4/6 Sequencing? ESR-1 not ready for prime time?…

CDK4/6i in first line and beyond & Biomarkers

The value of eHealth

Part 1: Important update on testosterone-recovery

Over-staging of bone scan compared with PSMA PET/CT

TALAPRO-2: Results and controversies

DEAR trial: real-world comparator analyses of ARIs

Part2: Important update on testosterone-recovery

Reassuring real-world data!

LuPARP combination study: LuPSMA and Olaparib in mCRPC

PRL-02: Intramuscular arbiraterone

Intensified or de-intensified therapy in mHSPC

ARASEC: ADT + Daralutamide for mHSPC

PSA nadir 6 month after Radiotherapy is strong…

PAPR-inhibitors: Patient-selection matters!

Confirming results for PARPi in mCRPC

AI for prediction in local prostate carcinoma

PEACE 1 - results and controversies

PSA nadir 6 månader efter radioterapi är en prognostisk…

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

PARP-inhibitors: La selección de pacientes es…

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

Intensifierad eller de-intensifierad behandling vid…

PARPi in PCa: more genetic testing is required as PRO…

Triple therapy in mCSPC - which is the ideal partner…

Q-TWiST in the therapy of aUC

Best of Bladder: ddMVC increases DFS! Standard…

Enfortumab vedotin + pembrolizumab 1stL in…

First line in cisplatin-ineligible advance urothelial…

Extent of lymphadenectomy in cystectomy

New standard for MIBC

Targeted therapies in advanced urothelial cancer: The…

FGFR inhibition

New SoC option for metastatic bladder cancer

Nouvelles options de soins standard pour le cancer de…

Terapias dirigidas al cáncer urotelial avanzado: ¡¿El…

Best of Bladder: ddMVC increases DFS! Standard…

The efficacy of neo-adjuvant therapy (ddMVAC,…

Update EV/Pembro, Avelumab Maintenance

Primary endpoint not reached: what do we learn from…

Non ccRCC: how should we treat patients today?

Long term follow up in advanced renal cell cancer: Is…

News from the adjuvant

Long-term follow-up for IO/TKI in mRCC

Update and take home message of 1st Line mRCC

New standard for 2nd line RCC?

IO rechallenge in mRCC

1st Line therapy RCC: which combination to choose?

New data non ccRCC

The value of perioperative chemo-IO in rNSCLC and the…

More options in the perioperative setting

CheckMate 9LA: 4‑year clinical update

Adjuvant and neoadjuvant strategies in resectable NSCLC

Added benefit of perioperative chemo/IO in stage 2-3b…

Perioperative treatment

A new standard of care

ADAURA - results and controversies

Role of periopertative IO confirmed

A chemo-free preop. IO strategy?

Another neoadjuvant chemo/IO option

An imperfect analysis, but perfect results

EGFR testing necessary in the adjuvant setting

Confirmation of neoadjuvant immunotherapy

ADAURA - Discussion closed?

OS benefit from EGFR receptor TKI

Which should we prefer: neoadjuvant, adjuvant or…

Induction options in the perioperative setting

A new standard of care for operated patients with…

ADAURA- discussie gesloten?

Rolle der periopertativen IO bestätigt

Que devrions-nous préférer: traitement néoadjuvant,…

Más opciones en el entorno perioperatorio

Un nouveau standard therapeutique pour les patients…

Toegevoegde waarde van periperatief chemo-immuno bij…

Pembro + chemo in pts with TKI-resistant EGFRm /…

Zorifertinib: an option when osimertinib is not…

Update on KRASG12Cm treatment options - how to proceed?

Does ADC + chemo + IO replace the existing concepts?

TTF-treatment requires further studies

TROP2-ADC shows high response rates in 1L-combination…

IO in EGRF positive patients post TKI

Stopping treatment is ok

CORRELATE - a real world analysis

ADC + ICI ± Pt-CT in patients with aNSCLC

New data from another BiTE

Hyperfractionated radiotherapy for SCLC

Can we incoporate biomarkers in SCLC treatment?

Treatment strategies in SCLC

More BiTEs, more possibilities

Stratégies de traitement dans le SCLC

Kunnen we biomarkers gebruiken om behandeling te…

ONCOalert (inclusive patient advocates) consensus on…

No practice-changing data in mesothelioma, other…